Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Soap-and-Water Bed Bath Versus Disposable Wipe Bath in the Same ICU Patients (YBU-BANYO)

30 ottobre 2026 aggiornato da: Ozhan Ozcan, Sinop Atatürk State Hospital

Within-Patient Comparison of Traditional Soap-and-Water Bed Bath and Disposable No-Rinse Wipe Bath on Procedural Pain Behavior, Comfort and Physiological Response in Adult Intensive Care Unit Patients: A Randomized Crossover Trial

Bed bathing is a routine nursing procedure in the intensive care unit (ICU). In the study units, every patient routinely receives both a traditional bed bath with warm water and soap (every 10 days) and a bath with pre-packaged, disposable, no-rinse wipes (every 3 days). Little is known about how these two methods compare for pain, comfort and physiological stress in the same patient.

The goal of this randomized crossover trial is to compare the two bathing methods within the same adult ICU patients. The main question it aims to answer is: Does pain-related behavior during the bath, measured with the Critical-Care Pain Observation Tool (CPOT) while the patient is turned to the side, differ between the soap-and-water bath and the wipe bath? Other questions include whether the methods differ in vital signs and body temperature after the bath, anxiety, comfort, feeling of cleanliness, satisfaction and preference in patients who can self-report, bath duration, nursing time, cost, and adverse events.

The routine bathing schedule does not change. Only the order of each participant's first two study baths is decided by chance: either soap-and-water first and wipes 72 hours later, or wipes first and soap-and-water 72 hours later. Each patient serves as his or her own control. The first minute of the first lateral turn in both baths is video-recorded (face, upper body and arms only) and scored by an assessor who does not know which method was used.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

Design: Single-center, prospective, randomized, two-period, two-sequence (wash-wipe / wipe-wash) crossover trial embedded in routine care, with blinded video-based assessment of the primary outcome. Setting: second-level (16 beds) and third-level (22 beds) adult ICUs, Sinop Atatürk State Hospital, Türkiye.

Routine care and schedule: All ICU patients routinely receive a whole-body soap-and-water bed bath every 10 days and a whole-body disposable wipe bath every 3 days. In the study, Session 1 is given within 24 hours after randomization with the method determined by the allocated sequence, and Session 2 is given with the other method 72 hours (±12 hours) later, which matches the routine 3-day interval. Thereafter, the routine schedule continues (soap-and-water every 10 days from the first wash; wipes every 3 days; if both fall on the same day, only the soap-and-water bath is given). Routine oral and perineal care continues. Additional baths are allowed when clinically needed.

Randomization: Sequences are allocated 1:1 using computer-generated lists with permuted blocks of 4 and 6, stratified by ICU level and communication status (Stratum A: able to self-report - RASS -1 to +1, CAM-ICU negative, able to use a visual analogue scale; Stratum B: unable to self-report). Allocation is concealed with sequentially numbered, opaque, sealed envelopes.

Interventions: Both methods cover the whole body in the same clean-to-dirty order with two lateral turns, two nurses, privacy measures, linen change and a standardized information script. Soap-and-water bath: warm water (43.5-46 °C), liquid soap, separate cloths and towels; each area is soaped, rinsed and towel-dried. Wipe bath: chlorhexidine-free, no-rinse disposable wipes warmed to ≤40 °C; a new wipe for each area, at least three passes with light pressure, air-dried.

Measurements: Full measurements are made in Sessions 1 and 2 at T0 (before the bath after ≥15 minutes of rest), during the bath, T1 (10 minutes after), T2 (30 minutes after) and during the 2 hours after the bath. CPOT and vital signs are recorded in all patients; Stratum A patients also rate anxiety (VAS-A), comfort, cleanliness and satisfaction, and state their preferred method after Session 2. For later routine baths, date, method, duration, materials and adverse events are recorded; skin is assessed at baseline, at each soap-and-water bath and at ICU discharge (descriptive only, because every patient receives both methods).

Blinding: The first minute of the first lateral turn in Sessions 1 and 2 is video-recorded with a hospital-owned, password-protected device (face, upper body and arms; ventilator screen in intubated patients; bathing materials and genital area excluded). Videos are coded without method or session information and scored in random order by an assessor not involved in bathing. The muscle tension item is taken from the in-room nurse. If no video is available, the in-room CPOT score is used. Videos are deleted after scoring.

Sample size: Assuming a clinically relevant within-patient difference of 1 CPOT point and a standard deviation of differences of 2.0 (dz = 0.5), two-sided alpha 0.05 and 80% power, 34 patients completing both sessions are required. Allowing about 15% loss before Session 2, 40 patients will be randomized.

Statistical analysis: Procedural CPOT will be analyzed with a linear mixed model including method, period, sequence and session-specific resting CPOT as fixed effects and patient as a random effect, adjusted for ICU level and stratum; all randomized patients contribute available data. Sensitivity analyses: Wilcoxon signed-rank test with Hodges-Lehmann estimate in completers, in-room scores, video-only sessions, adjustment for sedative infusions, and an ordinal mixed model. Secondary outcomes are analyzed with mixed models, McNemar tests or exact binomial test (preference), and interpreted as exploratory.

Safety: The bath is stopped if SpO2 < 90% for >1 minute, MAP < 65 mmHg or >20% fall, heart rate >130 or <50/min or new arrhythmia, RASS ≥ +2, tube or catheter displacement, or at the patient's request.

Tipo di studio

Osservativo

Iscrizione (Stimato)

72

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

Age 18 years or older. Admitted to the second- or third-level adult ICU within the previous 48 hours and expected to stay at least another 24 hours

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Admitted to the second- or third-level adult ICU within the previous 48 hours and expected to stay at least another 24 hours
  • Richmond Agitation-Sedation Scale (RASS) score between -3 and +1
  • Judged by the attending physician to be clinically suitable for a whole-body bed bath with two lateral turns
  • Hemodynamically stable: no vasopressor, or norepinephrine ≤ 0.1 µg/kg/min (or equivalent) without dose increase in the previous 6 hours
  • Written informed consent from the patient or the legal representative

Exclusion Criteria:

  • RASS ≤ -4 or ≥ +2
  • Use of neuromuscular blocking agents
  • End-of-life or exclusively palliative care
  • Severe neurological injury (brain death, Glasgow Coma Scale ≤ 8 not due to sedation)
  • Extensive skin damage (burns, widespread dermatitis, large open wounds) or known allergy to the wipe ingredients
  • Open abdomen, unstable spinal fracture, ECMO or any other condition preventing lateral turning
  • Initiation or dose change of anxiolytic or antipsychotic treatment within the previous 24 hours
  • Previous participation in this study within the last 30 days

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Soap-and-Water Bed Bath

Whole-body bed bath with warm water (43.5-46 °C) and liquid soap; each body area is soaped, rinsed and towel-dried; two lateral turns, two nurses. First bath within 24 hours after randomization, then every 10 days until ICU discharge.

Disposable Wipe Bath

Whole-body bed bath with pre-packaged, chlorhexidine-free, no-rinse disposable wipes warmed to ≤40 °C; a new wipe for each body area, no rinsing or towel-drying; two lateral turns, two nurses. Same schedule as the comparator arm.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Procedural pain behavior during the first lateral turn (CPOT)
Lasso di tempo: During the first study bath, at the first lateral turn (within 24 hours after randomization)

Critical-Care Pain Observation Tool (CPOT) total score (range 0-8; higher scores indicate more pain-related behavior), scored from a video recording of the first minute of the first lateral turn by an assessor blinded to group allocation. Compared between groups adjusted for resting CPOT at T0.

During the first study bath, at the first lateral turn (within 24 hours after randomization)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients with significant pain behavior during the bath
Lasso di tempo: During the first study bath (within 24 hours after randomization)

Proportion of patients with procedural CPOT score > 2 (range 0-8) during the first lateral turn of the first study bath.

During the first study bath (within 24 hours after randomization)
Post-bath CPOT score
Lasso di tempo: 10 and 30 minutes after the end of the first study bath

CPOT total score (0-8; higher = more pain-related behavior), adjusted for resting CPOT.

10 and 30 minutes after the end of the first study bath
Anxiety in patients able to self-report
Lasso di tempo: 10 and 30 minutes after the end of the first study bath

Visual analogue scale for anxiety (VAS-A; 0-10 cm; higher = more anxiety) in Stratum A patients, adjusted for the pre-bath score.

10 and 30 minutes after the end of the first study bath
Comfort, cleanliness and satisfaction in patients able to self-report
Lasso di tempo: 10 minutes after the end of the first study bath

Numeric rating scales (0-10; higher = better) for comfort, feeling clean and fresh, and satisfaction with the bath, in Stratum A patients

10 minutes after the end of the first study bath

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

10 novembre 2026

Completamento primario (Stimato)

10 febbraio 2027

Completamento dello studio (Stimato)

10 marzo 2027

Date di iscrizione allo studio

Primo inviato

30 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 ottobre 2026

Primo Inserito (Effettivo)

5 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SINOP UNV. 2026/149

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

De-identified individual participant data underlying the published results may be made available upon reasonable request to the principal investigator after publication, subject to approval by the ethics committee and in compliance with Turkish Personal Data Protection Law No. 6698. Video recordings will not be shared and will be deleted after scoring.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .